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Characterization of Pneumonitis in Patients with
Advanced Non-small Cell Lung Cancer Treated
with Everolimus (RAD001)
Dorothy A. White, MD,* Lawrence H. Schwartz, MD,* Sasa Dimitrijevic, PhD,†
Lilla Di Scala, PhD,† Wendy Hayes, Do,‡ and Stefan H. Gross, MSc†
Purpose: To assess the incidence and radiographic and clinical
presentation of pneumonitis associated with the mammalian target
of rapamycin inhibitor everolimus in patients with advanced non-
small cell lung cancer.
Patients and Methods: A retrospective, centralized review of
serial computed tomography scans and corresponding clinical
data from patients with advanced non-small cell lung cancer
treated with 10-mg oral once daily everolimus monotherapy in a
phase II clinical study was conducted. Serial chest CT scans
underwent a consensus read by two radiologists for presence of
pneumonitis. These cases were then reviewed with corresponding
clinical data by a pulmonologist to assess the suspected causality
to everolimus and outcome.
Results: Twenty-four of 64 patients reviewed were found to have
radiographic evidence of pneumonitis. In 16 of these 24 patients,
pneumonitis was suspected as either possibly (12) or probably (4)
related to everolimus. The most common radiographic manifesta-
tions were focal areas of consolidation at the lung bases or ground-
glass opacities. Pneumonitis evaluated with Common Terminology
Criteria for Adverse Events (version 3) was grade 1 or 2 in 12 of 16
suspected cases, with 4 patients experiencing higher grades. In most
of the patients, pneumonitis remained at the same or lower grade
without discontinuation of therapy. Patients with evidence of inter-
stitial lung disease at baseline had an increased risk of Common
Terminology Criteria for Adverse Events grade more than or equal
to 3 pneumonitis.
Conclusion: Within the limitation of this retrospective study,
results suggest that a mostly low-grade pneumonitis with a
possible or probable relationship to everolimus was relatively
frequent, occurring in 25% of evaluated patients. These results
suggest a need for monitoring of pulmonary adverse events and
the development of guidelines for managing pneumonitis in
future studies with everolimus.
Key Words: Pneumonitis, Non-small cell lung cancer, everolimus,
mTOR inhibitor, RAD001.
(J Thorac Oncol. 2009;4: 1357–1363)
Pneumonitis is a known side effect of inhibitors of themammalian target of rapamycin (mTOR) and has been
described for sirolimus (rapamycin, Rapamune, Wyeth Phar-
maceuticals Inc., Philadelphia, PA), temsirolimus (Torisel,
Wyeth Pharmaceuticals Inc., Philadelphia, PA), and everoli-
mus (Certican, Afinitor, Novartis Pharma AG, Basel, Swit-
zerland). It has been reported with sirolimus use in solid
organ transplantation,1,2 with an incidence of 5 to 15% and
presentation varied from asymptomatic radiographic abnor-
malities to a limited number of cases of significant respiratory
impairment. Most cases resolved with discontinuation or dose
reduction of sirolimus.3–7 Temsirolimus has also been asso-
ciated with pneumonitis in 1 to 5% of patients with cancer
enrolled in clinical studies, some patients with high-grade
toxicity, including rare fatalities.8–10 A incidence of radio-
graphic findings consistent with possible drug-induced pneu-
monitis was, however, reported in 36% of patients after an
independent review of serial chest radiographs and computed
tomography (CT) scans in patients treated for advanced
neuroendocrine tumors and endometrial carcinoma.11 Half of
them were asymptomatic, and treatment with temsirolimus
was continued in some cases without worsening of the pneu-
monitis. This higher incidence of lung toxicity was attributed
to increased detection because of the use of routine surveil-
lance chest CT.
Everolimus (RAD001) is an oral mTOR inhibitor mar-
keted for prevention of rejection in patients undergoing solid
organ transplantation (Certican, Novartis Pharma AG, Swit-
zerland) and refractory renal cell carcinoma (Afinitor, Novar-
tis Pharma AG, Switzerland). It is under clinical investigation
as an anticancer agent for various indications. In a phase III
trial of everolimus 10 mg daily versus placebo in advanced
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renal cell cancer, clinical pneumonitis was reported in 8% of
patients receiving everolimus, with higher grade toxicity seen
in 3%.12 Limited data in patients with breast cancer have
shown, similar to temsirolimus, a higher incidence of possible
low-grade pneumonitis.13
To further evaluate the incidence and nature of pneu-
monitis occurring in patients with advanced non-small cell
lung cancer (NSCLC) treated with everolimus,14 a retrospec-
tive evaluation of the radiographic patterns and clinical fea-
tures of pneumonitis was conducted.
PATIENTS AND METHODS
CT scans and study data were reviewed for patients
enrolled in a phase II study evaluating the efficacy of everoli-
mus monotherapy in patients with advanced NSCLC.14 All
patients had evidence of disease progression after treatment with
less than or equal to two chemotherapeutic regimens of which at
least one having been platinum based (Stratum 1) or less than or
equal to two chemotherapeutic regimens (at least one platinum
based) and additional treatment with a small molecule epidermal
growth factor receptor inhibitor (EGFRI) (gefitinib or erlotinib)
for at least 4 weeks (Stratum 2). Everolimus (10 mg) was given
orally once daily until disease progression or unacceptable
toxicity. In the case of unacceptable toxicity, everolimus was
reduced to 5 mg/d or treatment interrupted for a maximum of 2
weeks. Chronic treatment with corticosteroids or other immu-
nosuppressive agents was not permitted. Radiographic evalua-
tion was performed by CT scans every 4 weeks for the first 16
weeks of the study and then every 8 weeks thereafter.14
Serial chest CTs acquired from all patients with a
baseline and at least one follow-up scan if allowed by local
regulations were sent for independent review by two radiol-
ogists as a consensus read. All findings were categorized into
radiographic patterns, according to the criteria described by
Endo et al.15 with the addition of pattern E.
Y Pattern A: nonspecific areas of ground-glass attenuation
Y Pattern B: multifocal areas of airspace consolidation
Y Pattern C: pattern of patchy distribution of areas of
ground-glass attenuation (with or without interlobular
septal thickening)
Y Pattern D: extensive bilateral ground-glass attenuation
or airspace consolidations (without or with traction
bronchiectasis)
Y Pattern E: purely interstitial changes
Distribution (upper, mid, lower lobe, or diffuse) and
bilaterality of the lung changes were recorded as well as the
presence of associated pleural effusions.
All cases with pneumonitis developing during the
study were evaluated by an independent pulmonologist
using available clinical study data, including the patient’s
underlying medical conditions, prior treatments of radia-
tion and chemotherapy with their temporal relationship to
initiation of everolimus therapy and pneumonitis, symptoms,
laboratory data, and interventions by investigators. Summaries
of some cases, including those with higher grade toxicity are
described in the supplementary material. (Supplemental Digital
Content 1, http://links.lww.com/JTO/A8).
The causal relationship to everolimus was determined
as given below.
Y Probable: Pattern of clinical presentation and/or radio-
graphic manifestations, previously recognized with drug
induced lung disease, with temporal association to the
drug and the absence of any other obvious cause of
pneumonitis.
Y Possible: Presentation of clinical and/or radiographic
pattern atypical for drug toxicity but without other
obvious cause of pneumonitis or typical clinical
and/or radiographic presentation with the presence of
possible other causes where causality could not be
clearly determined.
Y Unlikely: Presentation of clinical and/or radiographic
pattern atypical for drug toxicity with strong evidence of
a cause of pneumonitis other than drug toxicity.
Y Unable to determine: Cases with limited information or
complex cases with multiple conditions present, which
made assessment unreliable.
Cases in which pneumonitis spontaneously resolved
while patient was on everolimus treatment were still included
as probably or possibly drug related if they met the above
criteria. Other possible causes for pneumonitis were noted
where applicable.
All data analyses conducted were descriptive including
the following.
Y Incidence of the pneumonitis and radiologic and clinical
characterization
Y Possible prognostic factors
Y Timing of onset
Y Severity by Common Terminology Criteria for Adverse
Events (CTCAE) version 3
Y Treatment
RESULTS
CT scans from 64 of 85 patients enrolled in the
clinical study were available for radiologic review. Of 64
patients reviewed, 27 (42.2%) had radiographic lung find-
ings suggestive of pneumonitis at any time point (baseline
or during study) (Table 1). Of these 27, 3 patients had
baseline radiographic findings that remained stable. The
other 24 patients (37.5%) had newly occurring or worsen-
ing radiographic findings during everolimus treatment con-
sistent with pneumonitis.
Patient Characteristics
Patient characteristics are given in Table 1. There was
no evident difference in age, sex, or prior radiotherapy (RT)
treatment between patients with or without pneumonitis. A
higher percentage of patients with pneumonitis had squamous
cell carcinoma (29.2% versus 15%), smoking history (87.5%
versus 62.5%), or grade 2 performance status (20.8% versus
12.5%) (Table 1). RT to the thorax had been received by 50%
of patients in those with and without pneumonitis. A total of
21 of 24 patients (87.4%) with pneumonitis had received
prior potentially pulmonary toxic anticancer medications,
including gemcitabine, docetaxel, paclitaxel, gefitinib, and
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erlotinib. The mean time from the end of this therapy to the
start of everolimus was 5.97 months with a median of 4.13
months.
Relationship to Study Treatment
Of the 24 pneumonitis cases, 16 were suspected to be
related to everolimus, 4 classified as probable (6.2% all
patients) and 12 as possible (18.7% all patients) (Table 2).
These patients will be referred to as “suspected pneumonitis.”
Patients in stratum 1 without receipt of an EGFRI had a
higher frequency of pneumonitis compared with stratum 2
patients who received an EGFRI (48.6 –24.1%). Other
causes of pneumonitis identified included infection, can-
cer, radiation, fluid overload, and toxicity from prior
anticancer medications.
In some cases, antibiotics and diuretics were given
making it impossible to totally exclude infection or fluid
overload as a contributing factor. In only three of eight
patients was RT completed less than 6 months before
treatment and was given in a location which could possibly
contribute to pneumonitis. Prior potential pulmonary toxic
chemotherapy was received in only 2 of 16 (12.5%)
“suspected patients” within 2 months of development of
pneumonitis.
Radiographic Features
Radiographic review of all 64 patients found that in 10
(15.6%) interstitial lung disease (ILD) was present at base-
line. Baseline ILD was present in 7 of 24 patients (29.2%)
who developed pneumonitis and in 3 of 40 (7.5%) who did
not (Table 3). Pneumonitis developed in two of five patients
TABLE 2. Pneumonitis: Drug-Relation and Other Suspected
Causes
Pneumonitis Patients
All
Patients
n (%)All n (%)
Stratum 1a
n (%)
Stratum 2b
n (%)
Cases 24/64 (37.5) 17/35 (48.6) 7/29 (24.1) 64
Relationship of
pneumonitis to
everolimus
Probably 4 (16.7) 2 (11.8) 2 (28.6) 4 (6.2)
Possibly 12 (50.0) 9 (52.9) 3 (42.9) 12 (18.7)
Unlikely 5 (20.8) 4 (23.5) 1 (14.3) 5 (7.8)
Unable to determine 3 (12.5) 2 (11.8) 1 (14.3) 3 (4.7)
Other suspected causes
of pneumonitisa
None 2 (8.3) 1 (5.9) 1 (14.3)
Infection 11 (45.8) 9 (52.9) 2 (28.6) NA
Cancer 8 (33.3) 5 (29.4) 3 (42.9) NA
Radiation 3 (12.5) 3 (17.6) 0 NA
Fluid overload 2 (8.3) 2 (11.8) 0 NA
Prior/concomitant
medication
1 (4.2) 0 1 (14.3) NA
Other 2 (8.3) 2 (11.8) 0 NA
aPatients may appear in
1 category
NA
a Patients who had not received an EGFRI.
b Patients who had received an EGFRI.
EGFRI, epidermal growth factor receptor inhibitor; NA, not applicable.
TABLE 3. Interstitial Lung Disease Present at Baseline
Pneumonitis
on Study
None
(N  40)
n (%)
Any
(N  24)
n (%)
Suspected
(N  16)
n (%)
ILD baseline 3 (7.5) 7 (29.1) 4 (25)
Stratum 1 2 4 2
Stratum 2 1 3 2
Pattern A 3 2 1
Pattern E 0 5 3
Focal 1 6 3
Diffuse 2 1 1
Unilateral 1 5 2
Bilateral 2 2 2
ILD, interstitial lung disease.
TABLE 1. Patient Characteristics
All Patients
(N  64)
n (%)
No
Pneumonitis
(N  40)
n (%)
Any
Pneumonitis
(N  24)
n (%)
Suspected
Pneumonitis
(N  16)
n (%)
Age: mean (range) 58.0 (21–74) 55.9 (21–72) 61.3 (42–74) 62.1 (42–74)
Sex
Male 34 (53.1) 19 (47.5) 15 (62.5) 9 (56.3)
Female 30 (46.9) 21 (52.5) 9 (37.5) 7 (43.8)
Race
Asian 11 (17.2) 9 (22.5) 2 (8.3) 1 (6.3)
Black 3 (4.7) 2 (5.0) 1 (4.2) 1 (6.3)
White 48 (75.0) 27 (67.5) 21 (87.5) 14 (87.5)
Other 1 (1.6) 1 (2.5) 0 0
Pacific Islander 1 (1.6) 1 (2.5) 0 0
Histology
Adenocarcinoma 36 (56.3) 26 (65.0) 10 (41.7) 7 (43.8)
Bronchioloalveolar
carcinoma
6 (9.4) 3 (7.5) 3 (12.5) 1 (6.3)
Large cell
carcinoma
6 (9.4) 4 (10.0) 2 (8.3) 2 (12.5)
Mixed epithelial cell
carcinoma
1 (1.6) 1 (2.5) 0 0
Other 2 (3.1) 0 2 (8.3) 1 (6.3)
Squamous cell
carcinoma
13 (20.3) 6 (15.0) 7 (29.2) 5 (31.3)
Stage current
IIIb 8 (12.5) 6 (15.0) 2 (8.3) 2 (12.5)
IV 56 (87.5) 34 (85.0) 22 (91.7) 14 (87.5)
WHO performance
status
0 20 (31.3) 13 (32.5) 7 (29.2) 3 (18.8)
1 33 (51.6) 21 (52.5) 12 (50.0) 9 (56.3)
2 10 (15.6) 5 (12.5) 5 (20.8) 4 (25.0)
Missing 1 (1.6) 1 (2.5) 0 0
Smoking status
Ever 47 (73.4) 26 (65.0) 21 (87.5) 15 (93.8)
Never 17 (26.6) 14 (35.0) 3 (12.5) 1 (6.3)
Prior thoracic RT
No 36 (56.3) 23 (57.5) 13 (54.2) 8 (50.0)
Yes 28 (43.8) 17 (42.5) 11 (45.8) 8 (50.0)
RT, radiotherapy.
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with baseline radiographic pattern A and all five patients with
baseline pattern E (Table 3). Baseline radiographic signs of
chronic obstructive pulmonary disease were present in 9 of 64
(14.1%), 7 of 24 (20.1%) who developed pneumonitis, and 2
of 40 (5.0%) in those who did not.
Radiographic patterns observed on CT scans during treat-
ment with everolimus in the 24 patients with pneumonitis were
predominantly ground-glass opacities (pattern A) or multifocal
areas of air space consolidation (pattern B) with a basilar and
peripheral predominance (Figures 1 and 2). The same profile
was observed in the 16 cases of “suspected pneumonitis.” One
patient with “suspected pneumonitis” had extensive airspace
consolidation following a more focal pattern of consolidation
and there were two cases of pure interstitial lung changes
(Figures 3 and 4). Radiographic patterns changed over observa-
tion points, most commonly between focal consolidation and
ground-glass opacities. In some cases with “suspected pneumo-
nitis,” radiographic findings persisted with four patients having
pneumonitis present for 8 to 11 months, while continuing treat-
ment with everolimus.
FIGURE 1. Probable case. Left, New
slight patchy focal infiltrate (Pattern
B) on right side—12 weeks. Middle,
Worsening focal infiltrate on right
side and ground-glass opacities on
left side—16 weeks. Right, Bilateral
patchy infiltrates/ground-glass opaci-
ties—20 weeks (Supplement: case 1).
FIGURE 2. Probable case. Left top, Baseline—bibasilar interstitial infiltrates (interstitial lung disease). Middle, New ground-
glass opacities (pattern A)—4 weeks. Right top, Bibasilar patchy infiltrates (pattern B)—12 weeks. Left bottom, Worsening infil-
trates—16 weeks. Right bottom, After dose reduction of everolimus for fatigue improved infiltrates are noted (Supplement:
case 3).
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Pleural effusions associated with the development of
any pneumonitis were noted in 7 patients, with 6 of the
effusions in 16 (37.5%) patients with “suspected pneumoni-
tis.” Pleural effusions were small in general, unilateral in four
cases and bilateral in two cases.
Clinical Presentation
Pneumonitis developed within 3 months after starting
treatment in 21 of 24 patients. The median time to onset in
stratum 1 patients was 65 days (95% confidence interval, 35
days; upper limit not reached) whereas it is not reached for
stratum 2 patients, with the probability of the event below 40%.
At diagnosis, only 6 of 24 patients (25%) with pneu-
monitis had respiratory or other symptoms potentially related
to the pulmonary process, but ultimately, 18 of 24 patients
(75%) became symptomatic. In the “suspected pneumonitis”
group, only 1 of 16 patients (6%) had symptoms at presen-
tation but 10 of 16 (62.5%) became symptomatic. The most
common symptom(s) were dyspnea in six patients, cough in
four, fatigue in three, and fever in two. Fatigue was not
considered a symptom if it was an isolated finding. Fever was
a sole symptom in one case described as infectious pneumo-
pathy with extensive infiltrates.
Only 3 relevant pulmonary adverse events (AEs) (of the
64 patients) were reported by the investigators during the
study and included CTCAE grade 2 “pneumopathy,” “pneu-
monitis,” and “infiltrative abnormalities.” Only one of these
(“infiltrative abnormalities”) was in the “suspected pneumo-
nitis” group. No interventions, such as bronchoscopy, were
performed for evaluation of any of these cases.
Severity/Outcome
Based on evaluation of AEs reported during the study,
the worst CTCAE grade was 1 or 2 in 18 of 24 patients (75%)
with pneumonitis, with 6 patients experiencing higher grade
toxicity, including 2 deaths (Table 4). At discontinuation
from study, pneumonitis resolved in 3 patients and 18 had
CTCAE grade 1/2. All CTCAE grade 3 patients improved,
with one grade 4 remaining (See case details of selected cases
in the Supplement). The worst CTCAE grade for the 16
patients with suspected pneumonitis was grade 1 or 2 in 12
patients (75%), with 4 patients having higher grades, includ-
ing 1 death. Toxicity for 2 of these 16 patients resolved by
end of study, with 12 being grade 1/2 and 1 grade 4 remaining
(Table 4).
FIGURE 3. Possible case. Left top,
Baseline—interstitial lung disease
with focal changes right. Right top,
New patchy focal unilateral abnor-
malities and small pleural effu-
sion—4 weeks. Left bottom, Exten-
sive infiltrates (pattern D)—8 weeks.
Right bottom, Marked improvement
with discontinuation of everolimus
therapy drug held and antibiotic
treatment—12 weeks (Supplement:
case 5).
FIGURE 4. Possible case. Left, Base-
line—interstitial lung disease (pattern
E) possibly from prior radiation.
Right, More extensive focal intersti-
tial changes (pattern E) at 4 weeks
(Supplement: case 9).
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A high incidence of baseline ILD was noted in 4 of
the 6 patients (67%) experiencing higher grade toxicity
(CTCAE grade 3 or above) with 3 (75%) of suspected
pneumonitis experiencing higher grade toxicity having
baseline ILD (Table 3).
Interruptions of treatment (2 weeks) occurred in four
patients of the “suspected pneumonitis” group, but only one
was for a pulmonary AE: grade 3 infectious pneumopathy,
which improved with antibiotics. One interruption was for
grade 3 fatigue, but pneumonitis was improved in temporal
relationship to interruption, and improvement was maintained
with resumption of everolimus at a reduced dose. Another
was for grade 3 stomatitis but respiratory failure occurred 4
days latter with progression of disease, and the drug was
discontinued. The last interruption was for grade 1 stomatitis.
In the “suspected pneumonitis” group, discontinuation
of the drug occurred in one patient due to CTCAE grade 4
respiratory failure and left lower lobe pneumonia. Three
patients, including one with “suspected pneumonitis,” re-
ceived a short course of corticosteroids for AEs other than
pneumonitis. A possible recurrence of pneumonitis was seen
in one case.
DISCUSSION
Drug-induced pneumonitis, described as noninfectious,
nonmalignant, radiologic evident infiltration in the lungs, is a
recognized complication of mTOR inhibitors in a small
percentage of patients. It is reported as relatively nonaggres-
sive and reversible on drug interruption or discontinua-
tion.1–10 Recent studies of mTOR inhibitors in patients with
advanced cancer undergoing evaluation by serial chest CT
scans have noted a significantly increased frequency of pa-
tients with “low-grade” pneumonitis, characterized as either
CTCAE grade 1 or 211,13 possibly related to use of serial chest
CT scanning in cancer patients. The lower reported incidence
of pneumonitis in transplant patients might also reflect the
routine use of multiple immunosuppressive agents, including
prednisone in this population.
The mechanism for pulmonary toxicity with mTOR
inhibitors is not fully understood but findings reported with
sirolimus suggest hypersensitivity phenomena. Bronchoal-
veolar lavage studies have reported lymphocytosis, particu-
larly with increased CD4 cells.3,5,16 Lung biopsies showed
bronchiolitis obliterans organizing pneumonia, lymphocytic
interstitial pneumonia, non-necrotizing granulomatous in-
flammation, and vasculitis.3,6,16,17 Pham et al.5 proposed that
sirolimus binds to plasma proteins and becomes immuno-
genic evoking a T-cell recognition with preferential differen-
tiation to TH1 cells and subsequent recruitment of an inflam-
matory response. Ongoing drug exposure may lead to a
persistent inflammatory cell response and low-grade pneumo-
nitis. The mechanisms of temsirolimus and everolimus asso-
ciated pneumonitis are speculative because of lack of detailed
studies. One patient in a phase I trial of everolimus in
advanced cancer was reported to have developed bronchioli-
tis obliterans organizing pneumonia.18
Because of limited data on the incidence and radio-
graphic and clinical features of pulmonary toxicity of everoli-
mus, we undertook this retrospective independent review of
radiographic findings of serial CT scans in patients receiving
the drug.
We found that 16 of 64 patients (25%) had radiographic
pneumonitis who on clinical review of available data were
possibly12 or probably4 related to everolimus. Pneumonitis
was identified within 3 months in the great majority of these
lung cancer patients. Most patients were asymptomatic at
detection of radiographic pneumonitis, but the majority de-
veloped respiratory or other symptoms potentially related to
pneumonitis during the course of study treatment. Radio-
graphic patterns observed most frequently were focal ground-
glass opacities or patchy areas of airspace consolidation
occurring commonly in the lung bases with some variation in
these patterns over time.
Cases of “suspected pneumonitis,” were CTCAE grade
1 or 2 in 75% of cases, with higher grade toxicity (3 or
higher) seen in four cases, including one death. Suspected
cases of pneumonitis resolved in 2 of 16 patients, and 14 of
16 patients showed persistent radiographic findings at the end
of study with or without associated symptoms over prolonged
observation while remaining on treatment. The effect of drug
interruption and/or corticosteroid therapy on pneumonitis was
not able to be determined.
Most of the cases were not recognized clinically as
pneumonitis by investigators. The low reporting of pneumo-
nitis-like events may have been due to the nonspecific radio-
graphic appearance and attribution of low-grade respiratory
symptoms in patients with advanced NSCLC and multiple
comorbidities to other causes.
Patients with ILD on baseline CT scans, whether focal
or diffuse, had a higher incidence of all types of pneumonitis
as well as CTCAE more than or equal to grade 3 pneumonitis
whether suspected as related to everolimus or another cause.
This may reflect the tendency of patients with underlying
lung disease to develop more serious toxicity in the setting of
any additional pulmonary process.
This study had several limitations. Although a variety
of findings can suggest drug-related toxicity, the diagnosis
remains a judgment based on combined radiographic and
clinical assessments. Patients with advanced NSCLC in this
study had relevant comorbidities including prior surgery, RT,
TABLE 4. Number of Patients with Pneumonitis and
Suspected Pneumonitis by CTC Grade
CTC
Grade
Any Pneumonitis
(N  24) (%)
Suspected Pneumonitis
(N  16)
Worst on Study End of Study Worst on Study End of Study
0 — 3 (12.5) — 2 (12.5)
1 6 (25.0) 9 (37.5) 5 (31.2) 7 (43.8)
2 12 (50.0) 9 (37.5) 7 (43.8) 5 (31.2)
3 3 (12.5) 0 (0.0) 2 (12.5) 0 (0.0)
4 1 (4.2) 1 (4.2) 1 (6.2) 1 (6.2)
5 2 (8.3) 2 (8.3) 1 (6.2) 1 (6.2)
Grade 5 corresponds to death and grade 0 at the end of study represents radio-
graphic resolution of the event.
CTC, Common Terminology Criteria.
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and other potential pulmonary-toxic therapies that could have
contributed to pulmonary infiltrates. An additional limitation
was the availability of full clinical information and follow-up
radiographs after study discontinuation. We also used a
strategy to be inclusive of all cases in which the drug could
have played a role and this may have overestimated the
incidence.
This study suggests that a pneumonitis, as assessed by
presence of radiographic findings on review of serial chest
CTs, was relatively common in patients with lung cancer
during treatment with everolimus, occurring in 25% of eval-
uated patients. In the majority of patients, these events were
low grade and persisted during ongoing treatment.
These results suggest a need for development of de-
tailed guidelines for managing pneumonitis in future clinical
trials with everolimus (Supplement: recommendations for
management of everolimus-related pneumonitis).
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